Skip to main content
Clinical Trials/CTRI/2014/05/004615
CTRI/2014/05/004615
Completed
Phase 4

A Prospective, Multi-centre, Observational Study to Profile Chronic Cholestatic Liver Diseases in Patient Population Receiving Udiliv in India - The Splendid Study

Abbott India Limited0 sites250 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: null- Chronic Cholestasis Liver Disease
Sponsor
Abbott India Limited
Enrollment
250
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Pms

Investigators

Eligibility Criteria

Inclusion Criteria

  • A patient can be included in the study if he/she meets all of the following inclusion criteria:
  • 1\. Adult male or non\-pregnant female patient aged 18 to 65 years.
  • 2\. Presence of chronic CLD as diagnosed by the physician.
  • 3\. A patient in whom the decision to prescribe Udiliv (according to the local label) has been taken by the treating physician during the normal course of therapy.
  • 4\. Patient who has given written authorization to provide data for the study.

Exclusion Criteria

  • Patients presenting with any of the following criteria will not be eligible for the study:
  • 1\. Contraindications to Udiliv treatment (including hypersensitivity) according to the local label.
  • 2\. Hepatocellular or metastatic liver carcinoma.
  • 3\. Severe liver disease including but not limited to ascites, hepatic encephalopathy, hypoalbuminemia, coagulopathy.
  • 4\. Child Pugh C Classification as diagnosed by the physician
  • 5\. Pregnancy or lactation.
  • 6\. Concomitant use of hepatotoxic drugs
  • 7\. Previous enrollment in the present study.
  • 8\. Other conditions that make the patientâ??s participation impossible (by investigator judgment).

Outcomes

Primary Outcomes

Not specified

Similar Trials